The buzz around biotechnology investing that could be felt this year at the J.P. Morgan Healthcare Conference could reach the beleaguered medical-device sector as well.
But it won’t be a spate of IPOs—and the headlines they generate–that re-ignites interest in device companies, several investors said.
"What we are really hoping to see in 2013 are great new products approved, and put on the market," said Ryan Drant, a general partner at New Enterprise Associates and a board member at the Medical Device Manufacturers Association.